What are the most recent findings on the... - tlooto, The Most Powerful AcademicGPT

The therapeutic profile of GLP-1 receptor agonists (GLP-1 RAs) has broadened substantially over the last five years, with robust evidence supporting benefits in glycemic control, weight reduction and emerging neuroprotective effects. Below is a concise, literature-backed synthesis of these domains. 1. Diabetes management and cardiovascular outcomes GLP-1 RAs such as semaglutide, liraglutide and dulaglutide consistently lower HbA1c by 1.0–1.5% versus placebo or active comparators, acting via glucose-dependent enhancement of insulin secretion, suppression of glucagon and delayed gastric emptying [1]. Large cardiovascular outcome trials (CVOTs) have demonstrated a 13–26% relative risk reduction in major adverse cardiovascular events (MACE) among high-risk T2D populations. For example, liraglutide (LEADER) and semaglutide (SUSTAIN-6) yielded hazard ratios of 0.87 and 0.74 for MACE, respectively [1], while dulaglutide (REWIND) showed similar benefits [2]. Post-hoc analyses indicate that the